Ryvu Therapeutics Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Pawel Przewiezlikowski

Algemeen directeur

zł1.1m

Totale compensatie

Percentage CEO-salaris	78.4%
Dienstverband CEO	no data
Eigendom CEO	17.4%
Management gemiddelde ambtstermijn	3.1yrs
Gemiddelde ambtstermijn bestuur	5.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Pawel Przewiezlikowski's beloning veranderd ten opzichte van Ryvu Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-zł104m
Jun 30 2024	n/a	n/a	-zł96m
Mar 31 2024	n/a	n/a	-zł94m
Dec 31 2023	zł1m	zł838k	-zł92m
Sep 30 2023	n/a	n/a	-zł73m
Jun 30 2023	n/a	n/a	-zł66m
Mar 31 2023	n/a	n/a	-zł75m
Dec 31 2022	zł341k	zł165k	-zł84m
Sep 30 2022	n/a	n/a	-zł94m
Jun 30 2022	n/a	n/a	-zł105m
Mar 31 2022	n/a	n/a	-zł92m
Dec 31 2021	zł1m	n/a	-zł79m
Sep 30 2021	n/a	n/a	-zł72m
Jun 30 2021	n/a	n/a	-zł61m
Mar 31 2021	n/a	n/a	-zł41m
Dec 31 2020	n/a	n/a	-zł32m
Sep 30 2020	n/a	n/a	-zł40m
Jun 30 2020	n/a	n/a	-zł32m
Mar 31 2020	n/a	n/a	-zł41m
Dec 31 2019	zł524k	zł524k	-zł44m
Sep 30 2019	n/a	n/a	-zł53m
Jun 30 2019	n/a	n/a	-zł60m
Mar 31 2019	n/a	n/a	-zł28m
Dec 31 2018	zł476k	zł476k	-zł23m
Sep 30 2018	n/a	n/a	zł2m
Jun 30 2018	n/a	n/a	zł14m
Mar 31 2018	n/a	n/a	zł21m
Dec 31 2017	zł655k	zł655k	zł6m

Compensatie versus markt: De totale vergoeding ($USD 260.14K ) Pawel } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 786.80K ).

Compensatie versus inkomsten: De vergoeding van Pawel is gestegen terwijl het bedrijf verliesgevend is.

CEO

Pawel Przewiezlikowski

no data

Tenure

zł1,068,120

Compensatie

Mr. Pawel Tadeusz Przewiezlikowski, MSc., MBA, serves as the Chief Executive Officer of BioCentrum Sp. z o.o. Mr. Przewiezlikowski serves as a Member of Supervisory Board of SELVITA S.A.Mr. Przewiezlikow...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Pawel Przewiezlikowski	Founder	no data	zł1.07m	17.44% € 42.1m
Krzysztof Brzózka	Executive VP	12.8yrs	zł1.43m	1.16% € 2.8m
Kamil Sitarz	COO & Member of the Management Board	4yrs	zł1.18m	0.17% € 409.7k
Vatnak Vat-Ho	Chief Business Officer & Member of Management Board	2.3yrs	zł2.22m	0.18% € 446.4k
Hendrik Nogai	Chief Medical Officer & Member of Management Board	2.3yrs	zł2.17m	0.058% € 141.0k
Paulina Wolanin	Human Resources Manager	no data	geen gegevens	geen gegevens

3.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van 9Y4 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Smith	Member of Supervisory Board	1.4yrs	zł90.15k	geen gegevens
Rafal Chwast	Independent Member of the Supervisory Board	no data	zł159.99k	0.52% € 1.3m
Tadeusz Wesolowski	Non-Independent Vice Chairman of Supervisory Board	no data	zł157.23k	0.40% € 970.9k
Scott Fields	Member of Supervisory Board	1.4yrs	zł121.27k	geen gegevens
Piotr Romanowski	Independent Chairman of the Supervisory Board	13.8yrs	zł159.78k	0.22% € 522.1k
Axel Glasmacher	Non-Independent Member of the Supervisory Board	5.2yrs	zł157.23k	geen gegevens
Thomas Turalski	Non-Independent Member of the Supervisory Board	5.2yrs	zł157.23k	0.087% € 209.9k

5.2yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 9Y4 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).

Ryvu Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Ryvu Therapeutics S.A., Annual General Meeting, Jun 27, 2024

Ryvu Therapeutics S.A., Annual General Meeting, Jun 14, 2023

Ryvu Therapeutics Announces Executive Changes

Ryvu Therapeutics S.A., Annual General Meeting, Jun 30, 2022

Recent updates

Third quarter 2024 earnings released: zł1.10 loss per share (vs zł0.79 loss in 3Q 2023)

Ryvu Therapeutics Announces Dosing of the First Patient in the Remark Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

New major risk - Financial position

Second quarter 2024 earnings released: zł1.40 loss per share (vs zł1.23 loss in 2Q 2023)

Ryvu Therapeutics S.A., Annual General Meeting, Jun 27, 2024

New major risk - Financial position

Full year 2023 earnings released: zł3.98 loss per share (vs zł4.56 loss in FY 2022)

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml

Ryvu Therapeutics S.A. to Report Q1, 2024 Results on May 15, 2024

Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023

Third quarter 2023 earnings released

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Second quarter 2023 earnings released

Ryvu Therapeutics S.A., Annual General Meeting, Jun 14, 2023

First quarter 2023 earnings released

Ryvu Therapeutics S.A. to Report Q3, 2023 Results on Nov 29, 2023

Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Ryvu Therapeutics S.A. announced that it expects to receive PLN 1.9 million in funding

Ryvu Therapeutics S.A. announced that it has received €22 million in funding from European Investment Bank, Investment Arm

Ryvu Therapeutics Announces Executive Changes

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics S.A., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: zł1.45 loss per share (vs zł0.74 loss in 1Q 2021)

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 At the 2022 European Hematology Association Congress

Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology Annual Meeting

Full year 2021 earnings: Revenues exceed analyst expectations

Ryvu Therapeutics S.A. Presents Clinical and Translational Data Updates At the 63rd American Society of Hematology Annual Meeting and the 44Th San Antonio Breast Cancer Symposium

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Ryvu Therapeutics S.A. Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors

Ryvu Therapeutics S.A. Announces FDA Lifts Partial Clinical Hold on Phase IB Clinical Trial of RVU120 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Ryvu Therapeutics Presents Positive Phase I Data for Rvu120 of Phase I/Ii Data for Sel24 Presented by Development Partner Menarini

Ryvu Therapeutics Announces Results SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

Ryvu Therapeutics S.A. Got Full Approval to Conduct Phase I/Ii Study of Rvu120 (Sel120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors in Poland

First quarter 2021 earnings released

Ryvu Therapeutics S.A. to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association

Full year 2020 earnings released

Ryvu Signs a Deal for Phase I Clinical Trials for its RVU120 Drug

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd